- Total operating expenses were $11.2M in Q3 2026 compared to $11.8M in Q3 2025.
- Operating loss for the quarter reached $11.2M as R&D spend was $3.87M.
- Patient screening in Phase 2a TSC-related epilepsy study expected by Q1 2027 following FDA hold lift.
Why is $FLNA moving today? · SEC 8-K archive
$FLNA SEC Filing Alert & Real-Time AI Stock Impact Analysis
T0 SEO archive for $FLNA: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).
FAQ: $FLNA filing catalyst
Why did $FLNA trigger an AI stock catalyst alert?
$FLNA triggered a Stock Catalyst AI alert on 2026-11-05 00:00:00 UTC for a SEC 8-K filing (AI Score: +0.5/10). Headline: Filana Therapeutics Reports Q3 Results; Phase 2a Screening to Start by Q1 2027. Key points: - Total operating expenses were $11.2M in Q3 2026 compared to $11.8M in Q3 2025. - Operating loss for the quarter reached $11.2M as R&D spend was $3.87M. - Patient screening in Phase 2a TSC-related epilepsy study expected by Q1 2027 following FDA hold lift.
How did $FLNA stock react after the SEC filing?
After the SEC 8-K for $FLNA, observed market reaction: T0 price $0.57. Past moves do not guarantee future results.
Where can I get real-time $FLNA SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $FLNA via Telegram and the VIP Web Terminal from €10/month.